The adverse skeletal effects of selective serotonin reuptake inhibitors

European Psychiatry

Volumn 27, Issue 3, 2012, Pages 156-169

  Tsapakis, E M ^a,b   Gamie, Z ^c   Tran, G T ^c   Adshead, S ^c   Lampard, A ^c   Mantalaris, A ^d   Tsiridis, E ^c,e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Aghios Charalambos Mental Health Centre   (Greece)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bone; Formation; Inhibitor; Resorption; Reuptake; Serotonin

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ESTROGEN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

BONE DENSITY; BONE DISEASE; BONE METABOLISM; BRADYCARDIA; COMORBIDITY; DEPRESSION; DOSE RESPONSE; DRUG MEGADOSE; EMBASE; FALL RISK; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LOW DRUG DOSE; MEDLINE; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SPINE FRACTURE; SYNCOPE; VERTEBRA FRACTURE; WRIST FRACTURE;

ANTIDEPRESSIVE AGENTS; BONE AND BONES; BONE DENSITY; DEPRESSIVE DISORDER; HUMANS; OSTEOPOROSIS; SEROTONIN UPTAKE INHIBITORS;

EID: 84858860189     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.10.006     Document Type: Short Survey

References (62)

1. Abrahamsen B., Brixen K. Mapping the prescriptiome to fractures in men--a national analysis of prescription history and fracture risk. Osteoporos Int 2009, 20(4):585-597.
2. Bab I., Yirmiya R., Depression Selective serotonin reuptake inhibitors, and osteoporosis. Current Osteoporosis Reports 2010, 8(4):185-191.
3. Battaglino R., et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004, 19(9):1420-1431.
4. Battaglino R., et al. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem 2007, 100(6):1387-1394.
5. Bliziotes M.M., et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 2001, 29(5):477-486.
6. Bliziotes M., et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 2006, 39(6):1313-1321.
7. Bolo N.R., Hode Y., Macher J.P. Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo. MAGMA 2004, 16(6):268-276.
8. Bolton J.M., et al. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 2008, 28(4):384-391.
9. Bonnet N., et al. Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling. Toxicol Appl Pharmacol 2007, 221(1):111-118.
10. Callebert J., et al. Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice. J Pharmacol Exp Ther 2006, 317(2):724-731.
11. Collet C., et al. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 2008, 22(2):418-427.
12. Cornea-Hebert V., et al. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 1999, 409(2):187-209.
13. Dahlstroem, A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand Suppl 1964;Suppl. 232:1-55.
14. Diem S.J., et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007, 167(12):1240-1245.
15. Dulawa S.C., et al. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29(7):1321-1330.
16. Elefteriou F., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434(7032):514-520.
17. Ensrud K.E., et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003, 163(8):949-957.
18. French D.D., et al. Outpatient medications and hip fractures in the US: a national veterans study. Drugs Aging 2005, 22(10):877-885.
19. Gill R.K., et al. Function, expression, and characterization of the serotonin transporter in the native human intestine. Am J Physiol Gastrointest Liver Physiol 2008, 294(1):G254-G262.
20. Graham S., et al. The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs 2008, 17(9):1281-1299.
21. Gustafsson B.I., et al. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 2006, 98(1):139-151.
22. Gustafsson B.I., et al. Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem 2006, 97(6):1283-1291.
23. Haney E.M., et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007, 167(12):1246-1251.
24. Hirai T., et al. Expression of mRNA for 5-HT2 receptors and proteins related to inactivation of 5-HT in mouse osteoblasts. J Pharmacol Sci 2009, 109(2):319-323.
25. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71(4):533-554.
26. Hubbard R., et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003, 158(1):77-84.
27. Kinjo M., et al. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005, 118(12):1414.
28. Launay J.M., et al. Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J 2006, 20(11):1843-1854.
29. Lewis C.E., et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007, 22(2):211-219.
30. [cited 2010 10/5/10]. http://www.whocc.no/atcddd/.
31. Liu B., et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998, 351(9112):1303-1307.
32. Locker M., et al. Stepwise control of osteogenic differentiation by 5-HT(2B) receptor signaling: nitric oxide production and phospholipase A2 activation. Cell Signal 2006, 18(5):628-639.
33. Lu N.Z., Bethea C.L. Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology 2002, 27(1):12-24.
34. McNicol A., Israels S.J. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999, 95(1):1-18.
35. McQueen J.K., Wilson H., Fink G. Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Brain Res Mol Brain Res 1997, 45(1):13-23.
36. McQueen J.K., et al. Serotonin transporter (SERT) mRNA and binding site densities in male rat brain affected by sex steroids. Brain Res Mol Brain Res 1999, 63(2):241-247.
37. Michelson D., et al. Bone mineral density in women with depression. N Engl J Med 1996, 335(16):1176-1181.
38. Nutt D.J., et al. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 1999, 9(Suppl. 3):S81-S86.
39. Pacher P., Ungvari Z. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses 2001, 57(4):469-471.
40. Resnick R.H., Gray S.J. Distribution of serotonin (5-hydroxytryptamine) in the human gastrointestinal tract. Gastroenterology 1961, 41:119-121.
41. Richards J.B., et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167(2):188-194.
42. Rosen C.J. Serotonin rising--the bone, brain, bowel connection. N Engl J Med 2009, 360(10):957-959.
43. Shi Y., et al. Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci U S A 2008, 105(51):20529-20533.
44. Spangler L., et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med 2008, 23(5):567-574.
45. Takeda S., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111(3):305-317.
46. Vane J.R. The release and fate of vaso-active hormones in the circulation. Br J Pharmacol 1969, 35(2):209-242.
47. Verdel B.M., Souverein P.C., Egberts T.C., van Staa T.P., Leufkens H.G., de Vries F. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 2010, 47(3):604-609.
48. Vestergaard P., Rejnmark L., Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006, 17(6):807-816.
49. Vestergaard P., Rejnmark L., Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008, 82(2):92-101.
50. Warden S.J., Haney E.M. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: Evidence from in vitro and animal-based studies. J Musculoskelet Neuronal Interact 2008, 8(2):121-132.
51. Warden S.J., et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005, 146(2):685-693.
52. Warden S.J., et al. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 2008, 15(6):1176-1183.
53. Warden S.J., et al. Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels. Bone 2010, 46(4):985-992.
54. Westbroek I., et al. Expression of serotonin receptors in bone. J Biol Chem 2001, 276(31):28961-28968.
55. Westbroek I., et al. Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 2007, 101(2):360-368.
56. Williams L.J., et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008, 23(2):84-87.
57. Yadav V.K., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135(5):825-837.
58. Yadav V.K., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138(5):976-989.
59. Zayzafoon M. Calcium/calmodulin signaling controls osteoblast growth and differentiation. J Cell Biochem 2006, 97(1):56-70.
60. Zhang X., et al. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004, 305(5681):217.
61. Zhou F.C., et al. Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 1998, 805(1-2):241-254.
62. Ziere G., et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008, 28(4):411-417.